Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.

Pharmacotherapy - 1 Nov 2016

Vaudo Christine E, Gil Brigitte, Galuski Kari, Zarwan Corrine, Nugent Francis W

Abstract excerpt

An antimetabolite pyridine analog, 5-fluorouracil (5-FU), is used to treat solid tumors. Early toxicities may occur at standard doses of 5-FU due to dihydropyrimidine dehydrogenase (DPD) deficiency. Uridine triacetate, approved by the Food and Drug Administration in 2015, is an oral prodrug of uridine, a pharmacologic antidote for 5-FU toxicity. To our knowledge, this is the first case report that documents the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetates
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anus Neoplasms

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fatigue

Share to Fluorouracil

Share to Neutrophils

Share to Uridine

Source

Identifiers

PMID: 27716991
DOI: 10.1002/phar.1841

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.PMID 27716991Read ↗

Review of the Fluoropyrimidine Antidote Uridine TriacetateSemantic proximity Read ↗

Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.Semantic proximity Read ↗

Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase 85T>C mutation is associated with ocular toxicity of 5-fluorouracil: a case report.Semantic proximity Read ↗

Defining the mode of action of cisplatin combined with a phosphoramidate modification of gemcitabineSemantic proximity Read ↗

Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.Semantic proximity Read ↗

A Heterodimeric Glucuronide Prodrug for Cancer Tritherapy: the Double Role of the Chemical AmplifierSemantic proximity Read ↗

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse modelsSemantic proximity Read ↗

Dihydropyrimidinones and -thiones with improved activity against human polyomavirus family membersSemantic proximity Read ↗

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNASemantic proximity Read ↗

Pulsed Azithromycin for the Treatment of Dacomitinib Induced Skin Toxicity in Patient with Tetracycline Intolerance – A Case ReportSemantic proximity Read ↗

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.